Mallinckrodt PLC's StrataGraft – a regenerative skin tissue therapy – appears closer to reaching the market after a long development road. The company announced on 9 June that it completed a rolling Biologics License Application for StrataGraft with the US Food and Drug Administration for the treatment of adult patients with deep partial-thickness (DPT) burns.
The pivotal Phase III trial supporting the submission was also presented at the virtual American Burn Association (ABA) annual meeting on 15 June and was selected as one of the "top five abstracts" by blinded reviewers
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?